TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04475445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transforaminal epidural steroid injection
Description: Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection
Description: Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
Study: NCT00956150

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID PO x 10 days
Study: NCT03000465

Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal surgery
Description: Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
Study: NCT00471601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT04166318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03188640

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic gastric-bypass surgery
Description: Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
Study: NCT01785745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive therapeutic exercise
Description: Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapeutic exercise
Description: Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
Study: NCT02063646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich extract
Description: Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
Study: NCT01081587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access to a Computerized Clinical Decision Support System (CCDDS)
Description: Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
Study: NCT04661124

Intervention type: DEVICE
Intervention: SPECTRALIS
Description: ophthalmic imaging device with head and chinrest

Intervention type: DEVICE
Intervention: SPECTRALIS
Description: ophthalmic imaging device with head and chinrest

Intervention type: DEVICE
Intervention: SPECTRALIS with Flex Module
Description: ophthalmic imaging device on mobile instrumentation stand

Intervention type: DEVICE
Intervention: SPECTRALIS with Flex Module
Description: ophthalmic imaging device on mobile instrumentation stand
Study: NCT02645266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
Study: NCT01081587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access to a Computerized Clinical Decision Support System (CCDDS)
Description: Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of Healthcare workers
Description: Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local assistance by a dietician
Description: Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
Study: NCT04088786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
Study: NCT00993720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
Study: NCT04458428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information.
Study: NCT00993720

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: continuous insulin therapy
Description: after optimal treatment with insulin, patients continue on insulin for four weeks
Study: NCT00772174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
Study: NCT03507608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 50mg flutamide prior to brachytherapy and prostatic biopsy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo prior to brachytherapy and prostatic biopsy
Study: NCT01150838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
Study: NCT04116554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine.
Description: 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0.9%saline
Description: 20 ml of 0.9%saline will be injected on each side
Study: NCT04886921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Description: Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
Study: NCT02124291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Assisted Hatching
Description: The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
Study: NCT00377676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloset
Description: Usual diabetes therapy plus Cycloset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Diabetes Therapy plus placebo
Description: Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
Study: NCT04378075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per the treatment arm description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vatiquinone-matching placebo will be administered per the treatment arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vatiquinone-matching placebo will be administered per the treatment arm description
Study: NCT01497379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical implantation of subretinal device
Description: surgical implantation of subretinal device

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgical implantation of subretinal device
Description: intra-individual implant OFF
Study: NCT01639898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: 2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
Study: NCT04432129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBIS II
Description: The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Service as Usual
Description: Service as usual consists of standard mental health care and vocational rehabilitation
Study: NCT01639898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: 9 cycles of the Len-Dex combination
Study: NCT03176394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLASTX Gel
Description: Foley Catheter lubricated with BLASTX Gel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: McKesson Jelly
Description: Foley Catheter lubricated with McKesson Jelly
Study: NCT02299661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093a
Description: DS-1093a, single oral doses up to 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093a
Description: DS-1093a, single oral doses up to 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093a
Description: DS-1093a, single oral doses up to 50 mg
Study: NCT03927989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging plus nicotine replacement therapy
Description: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care at Lung Cancer Screening
Description: Brief advice to quit smoking prior to lung cancer screening
Study: NCT04383769

Intervention type: OTHER
Intervention: questionnaires survey
Description: data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
Study: NCT04456764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SaFTiE
Description: A multi-modal fatigue risk management program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo Control
Description: A multi-modal teamwork assessment program.
Study: NCT00922610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
Study: NCT01831687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study: NCT02664038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Training
Description: Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Training
Description: Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
Study: NCT03609177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Communication Skills Training
Description: Communication skills training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Communication Skills Training
Description: Communication skills training

Intervention type: OTHER
Group type: OTHER
Intervention: Clinician Communication Skills Training
Description: Communication skills training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Communication Skills Training
Description: Communication skills training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids

Intervention type: OTHER
Group type: OTHER
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Declarations (ViDec)
Description: Recording of patient advance care planning videos

Intervention type: OTHER
Group type: OTHER
Intervention: Video Declarations (ViDec)
Description: Recording of patient advance care planning videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Declarations (ViDec)
Description: Recording of patient advance care planning videos
Study: NCT03903107

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional fluoroscopy guided Conduction System Pacing(CSP)
Description: conventional standard approach Conduction System Pacing(CSP) using fluoroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)
Description: Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
Study: NCT01073488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization, HBLSS and facility improvement
Description: Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
Study: NCT02504866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Description: Exercise training of vigorous intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light to moderate exercise
Description: Exercise training of light to moderate intensity
Study: NCT04368923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Patients receive oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients receive physical therapy
Study: NCT02928341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved water supply
Study: NCT00024518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30,000 units hrINF-alpha

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5,000 hrINF-alpha

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo was prepared as saline alone with 6mg human serum albumin (HSA).
Study: NCT04408443

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 + Vitamine D3
Description: Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil, medium chain triglycerides, silicon dioxide
Study: NCT01125423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study: NCT00870714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.